Trial reportSchizophrenia bulletin2023
Linking Personalized Brain Atrophy to Schizophrenia Network and Treatment Response.
Trial report in Schizophrenia bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Magnetic resonance imaging-based machine learning classification of schizophrenia spectrum disorders: a meta-analysis.Psychiatry and clinical neurosciences · 2024Pooled it
- Heterogeneous Brain Abnormalities in Schizophrenia Converge on a Common Network Associated With Symptom Remission.Schizophrenia bulletin · 2024Pooled it
- A lesion-derived brain network of somatic symptoms for transdiagnostic individual application.BMC medicine · 2026Article
- Distinct Biotypes of Visual Perception in Major Depressive Disorder.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Normative age-related structural brain deviations underlying psychopathology, cognitive impairment and neurological soft signs in schizophrenia spectrum disorders.Translational psychiatry · 2026Article
- Deciphering the Heterogeneity of Schizophrenia: A Multimodal and Multivariate Neuroimaging Framework for Unveiling Brain-Symptom Relationships and Underlying Subtypes.Schizophrenia bulletin · 2026Article
- Distinct antidepressant therapies act on a common brain network.Nature communications · 2026Article
- Beyond the cerebral cortex: cerebellar language-related subregions contributions to fluency in post-stroke aphasia.NeuroImage. Clinical · 2026Article
- A generalized epilepsy network derived from brain abnormalities and deep brain stimulation.Nature communications · 2025Article
- Divergent suicidal symptomatic activations converge on somato-cognitive action network in depression.Molecular psychiatry · 2024Article
- Heterogeneous Brain Atrophy Sites in Anxiety Disorders Map to a Common Brain Network.Depression and anxiety · 2024Article
- Altered functional dynamics gradient in schizophrenia with cigarette smoking.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and hypothesisSchizophrenia manifests with marked heterogeneity in both clinical presentation and underlying biology. Modeling individual differences within clinical cohorts is critical to translate knowledge reliably into clinical practice. We hypothesized that individualized brain atrophy in patients with schizophrenia may explain the heterogeneous outcomes of repetitive transcranial magnetic stimulation (rTMS). STUDY
designThe magnetic resonance imaging (MRI) data of 797 healthy subjects and 91 schizophrenia patients (between January 1, 2015, and December 31, 2020) were retrospectively selected from our hospital database. The healthy subjects were used to establish normative reference ranges for cortical thickness as a function of age and sex. Then, a schizophrenia patient's personalized atrophy map was computed as vertex-wise deviations from the normative model. Each patient's atrophy network was mapped using resting-state functional connectivity MRI from a subgroup of healthy subjects (n = 652). In total 52 of the 91 schizophrenia patients received rTMS in a randomized clinical trial (RCT). Their longitudinal symptom changes were adopted to test the clinical utility of the personalized atrophy map.
resultsThe personalized atrophy maps were highly heterogeneous across patients, but functionally converged to a putative schizophrenia network that comprised regions implicated by previous group-level findings. More importantly, retrospective analysis of rTMS-RCT data indicated that functional connectivity of the personalized atrophy maps with rTMS targets was significantly associated with the symptom outcomes of schizophrenia patients.
conclusionsNormative modeling can aid in mapping the personalized atrophy network associated with treatment outcomes of patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.